Known targets — ChEMBL curated mechanism
TUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TUBB8B
The experimentally established mechanism targets of Abt-751. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 2/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 2/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 2/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 2/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 2/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 2/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 2/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 2/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 2/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 2/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 2/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.58 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-751 SCHEMBL5023335 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Abt-751 SCHEMBL29355261 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8622853 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Abt-751 SCHEMBL5016878 | 0.99 | TUBB4A (0.98) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Abt-751 SCHEMBL5016898 | 0.96 | TUBB4A (0.92) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8625702 | 0.94 | TUBB4A (0.89) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8624355 | 0.91 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8629330 | 0.90 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8623536 | 0.90 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5692592 | 0.89 | TUBB4A (0.80) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | claimed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | claimed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | claimed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2009105123-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | claimed |
| US-7449584-B2 | N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1 | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | claimed |
| WO-2008103916-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | claimed |
| WO-2008079657-A1 | ANTITUMORIGENIC DRUG COMBINATION | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | claimed |
| US-20080153858-A1 | ANTITUMORIGENIC DRUG COMBINATION | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | claimed |
| EP-1644008-A2 | CONTINUOUS DOSING REGIMEN WITH ABT-751 | Abbott Laboratories (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005117903-A1 | TREATMENT OF CANCER IN PEDIATRIC PATIENTS | ABBOTT LABORATORIES (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050267166-A1 | Continuous dosing regimen | GORDON GARY | 2005-12-01 | — | — | US | claimed |
| US-20050075395-A1 | Continuous dosing regimen | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | claimed |
| WO-2004105794-A2 | CONTINUOUS DOSING REGIMEN WITH ABT-751 | ABBOTT LABORATORIES (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040242650-A1 | Extended dosing regimen | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | claimed |
| US-20040242649-A1 | Extended dosing regimen | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | claimed |
| EP-0472053-B1 | Sulfonamide derivatives | EISAI CO LTD (JP) | 1998-06-17 | — | — | EP | claimed |
| US-5250549-A | Antitumor agents | EISAI CO., LTD. (JP) | 1993-10-05 | — | — | US | claimed |
| EP-0472053-A2 | Sulfonamide derivatives | Eisai Co., Ltd. (JP) | 1992-02-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | TUBB4A 20/4885TUBB 7/4885TUBB4B 26/4885 |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | BDNF, NGF, NTRK2 | TUBB4A 19/4885TUBB 15/4885TUBB4B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.